Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WEGO 威高

山東威高集團醫用高分子製品股份有限公司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

VOLUNTARY ANNOUNCEMENT
FORMATION OF A JOINT VENTURE

This announcement is made by Shandong Weigao Group Medical Polymer Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors of the Company (the "**Board**") hereby announces that on 6 November 2025, Weigao International Holding Corporation Pte. Ltd. ("**Weigao International Holding**"), a wholly-owned subsidiary of the Company, entered into a joint venture agreement with PT Oneject Indonesia (the "**JV Partner**") in relation to the establishment of a joint venture, Oneject Wego Medical (the "**Joint Venture**"), in Indonesia. The Joint Venture will be held as to 45% by Weigao International Holding and as to 55% by the JV Partner. The Joint Venture will be accounted as a joint venture of the Company and its financial results will not be consolidated into the accounts of the Company.

The business activities of the Joint Venture include the manufacture and sale of intravenous catheter, infusion set and other medical consumables in Indonesia, which will continue to focus on localized production, targeting products that Indonesia currently relies heavily on imports.

* *For identification purpose only*

The JV Partner is a company incorporated in Indonesia and is a subsidiary of GDK Company, a leading Indonesian conglomerate that integrates manufacturing and sales operations. The JV Partner primarily produces standard syringes, safety and smart auto-disable syringes, blood bags, hemodialysis and blood collection tubes. As one of the leading manufacturers in Indonesia, the JV Partner enables the Joint Venture to leverage its extensive resources, established networks and in-depth market knowledge to identify suitable business opportunities in the Indonesian market. To the best of the knowledge of the Company, the ultimate beneficial owners of the JV Partner are independent of the Company and connected persons of the Company.

The Board is of the view that the formation of the Joint Venture will enable the Group to access new overseas markets, expand its customer base and create synergies with the existing business of the Group. In view of the above, the Board considered that the formation of the Joint Venture is in the interests of the Company and its shareholders as a whole.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Long Jing
Chairman

10 November 2025
Weihai, Shandong, the PRC

As at the date of this announcement, the Board comprises:

Mr. Long Jing *(Executive Director)*
Mr. Cong Rinan *(Executive Director)*
Mr. Lu Junqiang *(Executive Director)*
Mr. Wang Daoming *(Executive Director)*
Mr. Chen Lin *(Non-executive Director)*
Mr. Tang Zhengpeng *(Non-executive Director)*
Mr. Li Guohui *(Independent Non-executive Director)*
Mrs. Meng Hong *(Independent Non-executive Director)*
Mr. Li Qiang *(Independent Non-executive Director)*
Mr. Sun Heng *(Independent Non-executive Director)*

* *For identification purposes only*